Spring direct naar de hoofdnavigatie of de inhoud

Raygene Martier

Patent attorney

‘Optimally capitalize on your innovation. Activate your ideas.’
Raygene Martier

Raygene Martier

  • Life Sciences
  • Trainee Patent Attorney

Raygene Martier studied  Biomolecular Sciences  at VU Amsterdam with majors in molecular biology and  biochemistry. He gained work experience in both academia and industry.

Continue reading

He  has extended his  knowledge in areas such as gene therapy, neurology,  virology, microbiology, immunology, biochemistry, molecular biology, cell biology, diagnostics and medical biotechnology. He started his PhD in 2015 at the gene therapy company uniQure,  where he was responsible for development of RNAi-based gene therapies for differed neurodegenerative disorders. Here he also had the opportunity to support the IP department and became aware that R&D and IP go hand in hand.

Raygene  joined V.O. in 2019 as trainee patent attorney . He enjoys  being at the interface between science and Patent Law.

Education

  • PhD in RNAi-based gene therapies for  neurodegenerative disorders, Leiden U niversity/uniQure (2020)
  • MSc in Biomolecular Sciences, VU Amsterdam (2013)
  • BSc in Biotechnologie, Noordelijke Hogeschool Leeuwarden (2009)

Publications

  • Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Konstantinova P. (2019). Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic. Acids.14: 593-608.
  • Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Konstantinova P. (2019). Targeting RNA-Mediated toxicity in C9orf72 ALS and/or FTD by RNAi-Based gene Therapy. Mol. Ther. Nucleic. Acids.16: 26-37
  • Martier R, Sogorb Gonzalez M, Stricker-Shaver J, Hübener-Schmid J, Keskin S, Witjas J, van Deventer SJ, Konstantinova P, Phuc Nguyen H, Evers MM. (2019). Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Mol. Ther. Methods & Clinical Development Acids. https://doi.org/10.1016/j.omtm.2019.10.008.
  • Pietersz KL, Martier R, Baatje SM, Liefhebber JM, Brouwers CC, Pouw SM, Fokkert L, Lubelski J, Petry H, Martens GJM, van Deventer SJ, Konstantinova P, Blits B. (2019). Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther. Under submission.
  • Liefhebber, J., Martier, R., Van der Zon, T., Keskin, S., Huseinovic, A., Lubelski, J., Blits, B., Petry, H., Konstantinova, P. (2019) In depth characterization of a Mifepristone regulated expression system for AAV5-mediated gene therapy in the liver. Mol. Ther. Methods & Clinical Development.13: 512-525.
  • Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, Vallès A, van Deventer SJ, Konstantinova P, Evers MM. (2019) AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patientderived neuronal cultures and astrocytes. Mol. Ther: Methods & Clinical Development. doi: https://doi.org/10.1016/j.omtm.2019.09.010.
  • Miniarikova J, Zimmer V, Martier R, Brouwers C. C, Pythoud C, Richetin K, Konstantinova P. (2017). AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 24: 630-639.
  • Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Konstantinova P. (2016). Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease. Mol. Ther. Nucleic Acids: e297.
  • MacZuga P, Verheij J, Van Der Loos C, Van Logtenstein R, Hooijer G, Martier R, Konstantinova P. (2014). Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene. Ther. 21: 60-70.
  • Staszewski O, Baker RE, Ucher AJ, Martier R, Stavnezer J, Guikema JEJ. (2011). Activation-Induced Cytidine Deaminase Induces Reproducible DNA Breaks at Many Non-Ig Loci in Activated B Cells. Molecular Cell. 41(2): 232-242.

Languages

  • Dutch
  • English
  • Spanish
  • Papiamento

Also see these experts

Frits Schut

Frits Schut

  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner
Marijke Westra

Marijke Westra

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
More experts

News

V.O. advises companies through Wallonia subsidy program

The Wallonia Region (Wallonia, Belgium) is investing in the future of small and medium-sized companies in Wallonia. This government program enables businesses to spend a subsidy for each theme using ‘business checks’ (Chèques Entreprises) with qualified service providers. V.O. is one of these service providers.Continue reading

COVID-19 update 2

We hope this message finds you in good health. We previously informed you about the precautionary measures that we introduced in response to the COVID-19 outbreak. As a consequence, our office now operates in ’home-office mode’.Continue reading

UPC postponed

The introduction of the Unified Patent Court (UPC) has been postponed. This is due to a very recent ruling by the German Constitutional Court.Continue reading

Events

Knowledge for Growth 2020

Gent ICC, Ghent, Belgium

Don’t miss the 2020 edition on 10 September and capture the attention of 1,200 high-level life sciences actors from about 550 companies & organisations! The cream of the European life sciences community will be attending the 16th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech as well as investors, universities, topnotch research institutes, policymakers and competence providers. Continue reading

Sustainable Plastics & Materials Expo 2020

ATLAS Theater, Raadhuisplein 100, Emmen, Netherlands

The first edition of the Sustainable Plastics & Materials Expo 2020 will take place in Chemical Cluster Emmen in the Netherlands. Continue reading